Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
biphasic insulin aspart 50
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Considered generally healthy upon completion of medical history and physical examination, as judged by the Investigator or Sub-Investigator.
- Body Mass Index (BMI) between 19-29 kg/m^2 (inclusive)
- Fasting plasma glucose between 3.8-6.0 mmol/L (both inclusive)
Exclusion Criteria:
- Clinically significant abnormal haematology, biochemistry or urinalysis screening tests, as judged by the Investigator or Sub-Investigator
- Any serious systemic infectious disease that had occurred during the 4 weeks prior to the screening, as judged by the Investigator or Sub-Investigator
- Any inter-current illness that might affect blood glucose, as judged by the Investigator or Sub-Investigator
- Hepatitis B or C, or HIV (human immunodeficiency virus) positive
- Subjects with a first degree relative with diabetes mellitus
- History of or presence of diabetes, cancer or any clinically significant cardiac, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal, haematologic, neurologic, or psychiatric diseases or disorder
- Subjects who consumed more than 28 units of alcohol per week or who had a significant history of alcoholism or drug/chemical abuse
- Subjects who smoked more than 5 cigarettes per day
- Subjects who had taken part in strenuous exercise within 7 days prior to the screening
Sites / Locations
- Novo Nordisk Investigational Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Formulation A
Formulation B
Arm Description
Outcomes
Primary Outcome Measures
Area under the insulin aspart concentration-time curve in the interval from 0 to 16 hours
Cmax, maximum insulin aspart concentration
Secondary Outcome Measures
Area under the insulin aspart concentration-time curve
Tmax, time to maximum insulin aspart concentration
MRT, mean residence time
t½, terminal half-life
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01527630
Brief Title
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects
Official Title
A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Testing the Bioequivalence of Two Formulations of NN-X14Mix50 in Healthy Japanese Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
November 16, 2002 (Actual)
Primary Completion Date
January 8, 2003 (Actual)
Study Completion Date
January 8, 2003 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in Japan. The aim of this trial is to investigate the bioequivalence of two formulations of biphasic insulin aspart 50 (NN-X14Mix50) in healthy Japanese subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Formulation A
Arm Type
Experimental
Arm Title
Formulation B
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
biphasic insulin aspart 50
Intervention Description
A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
Primary Outcome Measure Information:
Title
Area under the insulin aspart concentration-time curve in the interval from 0 to 16 hours
Title
Cmax, maximum insulin aspart concentration
Secondary Outcome Measure Information:
Title
Area under the insulin aspart concentration-time curve
Title
Tmax, time to maximum insulin aspart concentration
Title
MRT, mean residence time
Title
t½, terminal half-life
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Considered generally healthy upon completion of medical history and physical examination, as judged by the Investigator or Sub-Investigator.
Body Mass Index (BMI) between 19-29 kg/m^2 (inclusive)
Fasting plasma glucose between 3.8-6.0 mmol/L (both inclusive)
Exclusion Criteria:
Clinically significant abnormal haematology, biochemistry or urinalysis screening tests, as judged by the Investigator or Sub-Investigator
Any serious systemic infectious disease that had occurred during the 4 weeks prior to the screening, as judged by the Investigator or Sub-Investigator
Any inter-current illness that might affect blood glucose, as judged by the Investigator or Sub-Investigator
Hepatitis B or C, or HIV (human immunodeficiency virus) positive
Subjects with a first degree relative with diabetes mellitus
History of or presence of diabetes, cancer or any clinically significant cardiac, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal, haematologic, neurologic, or psychiatric diseases or disorder
Subjects who consumed more than 28 units of alcohol per week or who had a significant history of alcoholism or drug/chemical abuse
Subjects who smoked more than 5 cigarettes per day
Subjects who had taken part in strenuous exercise within 7 days prior to the screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Tokyo
ZIP/Postal Code
1000005
Country
Japan
12. IPD Sharing Statement
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects
We'll reach out to this number within 24 hrs